home
Chi Siamo – Contatti
Servizi
Equity & Credit research
ESG
Legal
Apr 24, 2025
FY24 in line, in FY25 leaner costs and rising sales
marco
Società
,
Ulisse Biomed
«
Margins First: Farmacosmo’s Wellness Reset
»
FY24 in line, but challenging FY25E